Hints and tips:
Related Special Reports
...Rival biotech group Intellia Therapeutics plans to seek US approval for its own trial in the second half of 2020....
...AstraZeneca Plc has made a preliminary approach to rival drugmaker Gilead Sciences Inc. about a potential merger, according to people familiar with the matter, in what would be the biggest health-care deal...
...DD’s Indap v NYU’s Damodaran: Is stock compensation good or bad?...
...According to Ben Shepherd, director of therapeutics at Organovo, the challenges ahead are about increasing the size of the tissue that can be grown....
...Regulus Therapeutics gained 10 per cent to $17.89, after analysts at Deutsche Bank initiated coverage of the drug developer with a “buy” rating and a $30 price target....
...Jo Hayes Ward uses 3D printing to create the moulds for her gold jewellery. The pixellated look is a coincidence, she says: it comes from her love of building larger pieces out of small elements....
International Edition